Anti-CAB39 Polyclonal Antibody

Cat: K007771P

Summary:

【**Product name**】: Anti-CAB39 antibody

【**Source**】: Rabbit

【**Isotype**】: IgG

【**Species reactivity**】: Human Mouse

【**Swiss Prot**】: Q9Y376

【**Gene ID**】: 51719

【**Calculated**】: MW:40kDa

【**Observed**】: MW:40kDa

【**Purification**】: Affinity purification

【**Tested applications**】: WB IHC

【**Recommended dilution**】: WB 1:500-2000. IHC 1:50-200.

【**WB Positive sample**】: 293T,HeLa

【**IHC Positive sample**】: Human stomach cancer

【**Subcellular location**】: Cytoplasm Nucleus

【**Immunogen**】: A synthetic peptide of human CAB39

【**Storage**】: Shipped at 4°C. Upon delivery aliquot and store at -20°C

Background:

Peutz-Jeghers Syndrome (PJS) is a rare hereditary disease characterized by melanocytic macules of the lips, gastrointestinal hamartomatous polyps and an increased risk for many classes of cancer. The serine/threonine kinase LKB1 (also designated STK11) has been identified as the gene mutated in PJS. LKB1 activity increases upon the binding of a regulatory complex consisting of the STE20-related adaptor-alpha (STRAD alpha) pseudo kinase and the calcium binding protein 39 (MO25 alpha). STRAD and MO25 determine the subcellular localization of LKB1 by initiating its translocation from the nucleus to the cytoplasm, thus regulating the tumor suppressor activity of LKB1. The LKB1/STRAD/MO25 complex acts as an AMP-activated protein kinase kinase (AMPKK).

Verified picture



Western blot analysis with CAB39 antibody diluted at 1:1000;Lane: 293T,HeLa



Immunohistochemistry of paraffin-embedded Human stomach cancer with CAB39 antibody diluted at 1:50